Hederacolchiside A1CAS# 106577-39-3 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 106577-39-3 | SDF | Download SDF |
| PubChem ID | 11622076 | Appearance | White powder |
| Formula | C47H76O16 | M.Wt | 897.10 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Synonyms | Raddeanin R13; Raddeanoside R13 | ||
| Solubility | Soluble in methanol and pyridine | ||
| Chemical Name | (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-4-hydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid | ||
| SMILES | CC1C(C(C(C(O1)OC2C(C(COC2OC3CCC4(C(C3(C)C)CCC5(C4CC=C6C5(CCC7(C6CC(CC7)(C)C)C(=O)O)C)C)C)OC8C(C(C(C(O8)CO)O)O)O)O)O)O)O | ||
| Standard InChIKey | FYSAXYBPXKLMJO-IFECXJOTSA-N | ||
| Standard InChI | InChI=1S/C47H76O16/c1-22-30(49)33(52)35(54)38(59-22)63-37-32(51)26(61-39-36(55)34(53)31(50)25(20-48)60-39)21-58-40(37)62-29-12-13-44(6)27(43(29,4)5)11-14-46(8)28(44)10-9-23-24-19-42(2,3)15-17-47(24,41(56)57)18-16-45(23,46)7/h9,22,24-40,48-55H,10-21H2,1-8H3,(H,56,57)/t22-,24-,25+,26-,27-,28+,29-,30-,31+,32-,33+,34-,35+,36+,37+,38-,39-,40-,44-,45+,46+,47-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Hederacolchiside A1 shows antiproliferation activities in three cancer cell lines with the IC50 value of 2.4 uM. 2. Hederacolchiside A1 has antimelanoma potential. 3. Hederacolchiside A1 exhibits a preferential cytotoxicity on a pigmented melanoma cell line. 4. Hederacolchiside A1 shows anti-leishmanial activity, it exhibits a strong antiproliferative activity on all stages of development of the parasite by altering membrane integrity and potential. |
| Targets | MEK | ERK | Antifection |
Hederacolchiside A1 Dilution Calculator
Hederacolchiside A1 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.1147 mL | 5.5735 mL | 11.147 mL | 22.2941 mL | 27.8676 mL |
| 5 mM | 0.2229 mL | 1.1147 mL | 2.2294 mL | 4.4588 mL | 5.5735 mL |
| 10 mM | 0.1115 mL | 0.5574 mL | 1.1147 mL | 2.2294 mL | 2.7868 mL |
| 50 mM | 0.0223 mL | 0.1115 mL | 0.2229 mL | 0.4459 mL | 0.5574 mL |
| 100 mM | 0.0111 mL | 0.0557 mL | 0.1115 mL | 0.2229 mL | 0.2787 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Parstatin (mouse)
Catalog No.:BCC6042
CAS No.:1065756-01-5
- Parstatin (human)
Catalog No.:BCC6041
CAS No.:1065755-99-8
- 7-Amino-4-methylcoumarin-3-acetic acid
Catalog No.:BCN2562
CAS No.:106562-32-7
- SMND-309
Catalog No.:BCC1956
CAS No.:1065559-56-9
- Dafadine-A
Catalog No.:BCC5406
CAS No.:1065506-69-5
- Ganodermanontriol
Catalog No.:BCN5872
CAS No.:106518-63-2
- Ganoderiol A
Catalog No.:BCN8158
CAS No.:106518-61-0
- Boldenone cyclopentanepropionate
Catalog No.:BCC8894
CAS No.:106505-90-2
- Boc-D-Phenylalaninol
Catalog No.:BCC2714
CAS No.:106454-69-7
- Korepimedoside A
Catalog No.:BCN7887
CAS No.:106441-31-0
- Acid Black 1
Catalog No.:BCC8806
CAS No.:1064-48-8
- Deoxymorellin
Catalog No.:BCN3067
CAS No.:1064-34-2
- 3,10-Dihydroxy-5,11-dielmenthadiene-4,9-dione
Catalog No.:BCN1633
CAS No.:106623-23-8
- Qingyangshengenin A
Catalog No.:BCN8126
CAS No.:106644-33-1
- Trachelosiaside
Catalog No.:BCN7743
CAS No.:106647-12-5
- Matairesinol 4'-O-beta-gentiobioside
Catalog No.:BCN2848
CAS No.:106647-14-7
- Boc-D-Lys-OH
Catalog No.:BCC3420
CAS No.:106719-44-2
- Olprinone
Catalog No.:BCC1820
CAS No.:106730-54-5
- GYY 4137 morpholine salt
Catalog No.:BCC7739
CAS No.:106740-09-4
- 24-Deacetylalisol O
Catalog No.:BCN3365
CAS No.:1067510-31-9
- Otophylloside B
Catalog No.:BCN7267
CAS No.:106758-54-7
- Diethyl Acetamidomalonate
Catalog No.:BCC2841
CAS No.:1068-90-2
- BIBP 3226 trifluoroacetate
Catalog No.:BCC7456
CAS No.:1068148-47-9
- 5-Allyl-3-methoxy-6-methyl-7-(3,4,5-trimethoxyphenyl)bicyclo[3.2.1]oct-3-ene-2,8-dione
Catalog No.:BCN1632
CAS No.:106894-43-3
Antileishmanial activity of three saponins isolated from ivy, alpha-hederin, beta-hederin and hederacolchiside A1, as compared to their action on mammalian cells cultured in vitro.[Pubmed:10865451]
Planta Med. 2000 May;66(4):343-7.
The in vitro antileishmanial activity of three saponins isolated from ivy, alpha-hederin, beta-hederin and Hederacolchiside A1, was investigated on Leishmania infantum. The assessment of possible targets (membrane integrity, membrane potential, DNA synthesis and protein content) was performed in both Leishmania promastigotes and human monocytes (THP1 cells). Results observed in Leishmania showed that the saponins exhibited a strong antiproliferative activity on all stages of development of the parasite by altering membrane integrity and potential: Hederacolchiside A1 appeared to be the most active compound against both promastigotes and amastigotes. Results observed in THP1 cells demonstrated that the saponins exerted also a potent antiproliferative activity against human monocytes, by producing a significant DNA synthesis inhibition. The ratio between antileishmanial activity on amastigotes and toxicity to human cells suggested that the saponins could be considered as possible antileishmanial drugs.
Inhibition of HUVEC tubulogenesis by hederacolchiside-A1 is associated with plasma membrane cholesterol sequestration and activation of the Ha-Ras/MEK/ERK cascade.[Pubmed:15490165]
Cancer Chemother Pharmacol. 2004 Nov;54(5):432-40.
PURPOSE: Neoangiogenesis is critical to cancer proliferation and metastasis and constitutes an attractive target for cancer therapy. It has previously been demonstrated that hederacolchiside-A1 (HCol-A1), a triterpenoid saponin from Hedera colchica Koch, has antimelanoma potential. The goal of this study was to evaluate, in vitro, if in addition to its tumoricidal effect on melanoma cells, HCol-A1 might affect endothelial cell network formation. METHODS: We investigated whether HCol-A1 affects matrigel-induced tubulogenesis and inhibits the viability (WST-1 assay) of human umbilical vein endothelial cells (HUVECs). To provide structure-activity relationships (SAR), studies were conducted on HCol-A1, oleanolic acid and hederacolchiside A (HCol-A), a triterpenoid saponin which possess the same sugar sequence as Hcol-A1. Plasma membrane cholesterol sequestration was studied by labelling with [3H]cholesterol and assayed with HCol-A1-cholesterol complexes. HCol-A1 signalling was investigated using immunoassays. RESULTS: In contrast to HCol-A and oleanolic acid, HCol-A1 inhibited matrigel-induced angiogenesis at micromolar concentration. Plasma membrane cholesterol sequestration was found to be critical for this activity. Activation of the Ras/MEK/ERK cascade appears to be one of the mechanisms by which Hcol-A1 affects HUVEC network formation. The predominant activation of the Ha-Ras isoform, which decreases HUVEC-tolerance to apoptosis, might contribute to the high susceptibility of this cell line to HCol-A1. CONCLUSION: Since cholesterol sequestration affects cell confluence-dependent remodelling of endothelial membranes and vascular endothelial growth factor receptor-2 activity, these results raise the possibility that Hcol-A1 might slow-down cancer proliferation and metastasis in vivo by inhibiting critical aspects of neoangiogenesis. Further in vivo studies are needed to verify this hypothesis.
Synthesis and cytotoxicity of oleanolic acid trisaccharide saponins.[Pubmed:28273565]
Carbohydr Res. 2017 Apr 10;442:9-16.
An array of oleanolic acid-type saponins based on beta-hederin has been synthesized in a linear or one-pot manner. The cell viability assays indicate that synthetic saponins show antiproliferation activities in three cancer cell lines with IC50 values of 2.4-15.1 muM and Hederacolchiside A1 being the most potent. The results demonstrate that the type of terminal monosaccharides and linkage position have apparent effects on cytotoxicities and selectivities of these saponins against cancer cell lines tested. This study is helpful for future development of more potent anticancer leads.
In addition to membrane injury, an affinity for melanin might be involved in the high sensitivity of human melanoma cells to hederacolchiside A1.[Pubmed:15057038]
Melanoma Res. 2004 Apr;14(2):97-105.
We previously reported that Hederacolchiside A1 (Hcol A1), a new oleanene saponin isolated from Hedera colchica Koch (Araliaceae) exhibits a preferential cytotoxicity on a pigmented melanoma cell line. The present study confirms the high susceptibility of melanoma cell lines to this drug and shows concentrations producing a 50% decrease in cell content (IC50 values) inversely proportional to the melanin content of each cell line. At cytotoxic concentrations, Hcol A1 induces membrane-damaging effects within 6 h, cytoplasmic vacuolization within 24 h, and non-apoptotic cell death within 48 h. Using a new high-resolution magic-angle spinning nuclear magnetic resonance method, we have shown for the first time that this hederasaponin specifically interacts with melanin. The dissociation constant (2.7 mM) is comparable to those observed with drugs known to interact with melanin. Taking into consideration that the IC50 values were inversely proportional to the melanin in each cell line, our data suggest that, in addition to the delayed membrane injury induced by this drug, the ability of Hcol A1 to bind melanin could contribute to the higher toxicity of Hcol A1 in pigmented melanoma cells.
